165 related articles for article (PubMed ID: 30733972)
1. A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan.
Qiu W; Zhang C; Wang S; Yu X; Wang Q; Zeng D; Du P; Ma J; Zheng Y; Pang B; Yu Y; Long F; Pang X; Sun Z
J Immunol Res; 2019; 2019():3017360. PubMed ID: 30733972
[TBL] [Abstract][Full Text] [Related]
2. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.
Wild R; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Luo FR; Camuso A; McGlinchey K; Rose WC
Mol Cancer Ther; 2006 Jan; 5(1):104-13. PubMed ID: 16432168
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
[TBL] [Abstract][Full Text] [Related]
5. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new dual-targeting fully human antibody with potent antitumor activity against nasopharyngeal carcinoma.
Xie S; Zhu X; Li Y; Li L; Si Y; Yang N
Biol Chem; 2015 Aug; 396(8):917-21. PubMed ID: 25429597
[TBL] [Abstract][Full Text] [Related]
7. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
Wen F; Li Q
World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
[TBL] [Abstract][Full Text] [Related]
8. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer.
Park JE; Jin MH; Hur M; Nam AR; Bang JH; Won J; Oh DY; Bang YJ
Gastric Cancer; 2019 Sep; 22(5):932-940. PubMed ID: 30815759
[TBL] [Abstract][Full Text] [Related]
9. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.
Rios-Doria J; Sabol D; Chesebrough J; Stewart D; Xu L; Tammali R; Cheng L; Du Q; Schifferli K; Rothstein R; Leow CC; Heidbrink-Thompson J; Jin X; Gao C; Friedman J; Wilkinson B; Damschroder M; Pierce AJ; Hollingsworth RE; Tice DA; Michelotti EF
Mol Cancer Ther; 2015 Jul; 14(7):1637-49. PubMed ID: 25948294
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
12. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
13. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
[TBL] [Abstract][Full Text] [Related]
14. Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
Prewett M; Bassi R; Paz K; Amatulli M; Deevi D; Li H; Wang S; Witte L; Samakoglu S; Tonra JR
Anticancer Res; 2011 Jun; 31(6):2149-60. PubMed ID: 21737635
[TBL] [Abstract][Full Text] [Related]
15. Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.
Yi CH; Ruan CP; Wang H; Xu XY; Zhao YP; Fang M; Ji J; Gu X; Gao CF
Acta Pharmacol Sin; 2014 Nov; 35(11):1439-46. PubMed ID: 25263334
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
17. Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12.
Dong Q; Shi B; Zhou M; Gao H; Luo X; Li Z; Jiang H
Front Med; 2019 Feb; 13(1):83-93. PubMed ID: 30671888
[TBL] [Abstract][Full Text] [Related]
18. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
[TBL] [Abstract][Full Text] [Related]
20. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
